BioMarin Pharmaceutical Inc. (BMRN) Holdings Lifted by Los Angeles Capital Management & Equity Research Inc.

Los Angeles Capital Management & Equity Research Inc. grew its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 121.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 73,551 shares of the biotechnology company’s stock after purchasing an additional 40,357 shares during the quarter. Los Angeles Capital Management & Equity Research Inc.’s holdings in BioMarin Pharmaceutical were worth $6,845,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the business. Toronto Dominion Bank lifted its stake in shares of BioMarin Pharmaceutical by 246.9% during the 3rd quarter. Toronto Dominion Bank now owns 7,369 shares of the biotechnology company’s stock worth $686,000 after purchasing an additional 5,245 shares during the period. New York State Common Retirement Fund lifted its stake in shares of BioMarin Pharmaceutical by 1.5% during the 3rd quarter. New York State Common Retirement Fund now owns 485,790 shares of the biotechnology company’s stock worth $45,212,000 after purchasing an additional 7,000 shares during the period. CIBC Asset Management Inc lifted its stake in shares of BioMarin Pharmaceutical by 6.7% during the 3rd quarter. CIBC Asset Management Inc now owns 13,356 shares of the biotechnology company’s stock worth $1,243,000 after purchasing an additional 838 shares during the period. Grandfield & Dodd LLC lifted its stake in shares of BioMarin Pharmaceutical by 11.1% during the 3rd quarter. Grandfield & Dodd LLC now owns 6,497 shares of the biotechnology company’s stock worth $605,000 after purchasing an additional 650 shares during the period. Finally, BNP Paribas Arbitrage SA lifted its stake in shares of BioMarin Pharmaceutical by 163.2% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 55,521 shares of the biotechnology company’s stock worth $5,167,000 after purchasing an additional 34,430 shares during the period. 95.98% of the stock is currently owned by institutional investors.

In other news, insider Henry J. Fuchs sold 15,000 shares of the firm’s stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $90.50, for a total transaction of $1,357,500.00. Following the completion of the sale, the insider now directly owns 141,422 shares in the company, valued at $12,798,691. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jeffrey Robert Ajer sold 3,521 shares of the firm’s stock in a transaction dated Friday, September 22nd. The shares were sold at an average price of $95.00, for a total value of $334,495.00. Following the sale, the executive vice president now owns 49,299 shares of the company’s stock, valued at $4,683,405. The disclosure for this sale can be found here. Insiders have sold 40,686 shares of company stock valued at $3,736,318 over the last 90 days. Insiders own 1.85% of the company’s stock.

A number of research analysts have weighed in on the company. Zacks Investment Research lowered BioMarin Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. Morgan Stanley reissued an “overweight” rating and set a $117.00 price target (up previously from $115.00) on shares of BioMarin Pharmaceutical in a research note on Friday, October 6th. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and set a $129.00 price target on shares of BioMarin Pharmaceutical in a research note on Friday, October 6th. Jefferies Group LLC reissued a “buy” rating and set a $116.00 price target on shares of BioMarin Pharmaceutical in a research note on Tuesday, September 26th. Finally, Piper Jaffray Companies initiated coverage on BioMarin Pharmaceutical in a research note on Thursday, September 14th. They set an “overweight” rating and a $113.00 price target on the stock. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and sixteen have assigned a buy rating to the company. BioMarin Pharmaceutical presently has a consensus rating of “Hold” and an average target price of $111.55.

Shares of BioMarin Pharmaceutical Inc. (NASDAQ BMRN) opened at $82.88 on Monday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.81 and a current ratio of 4.91. BioMarin Pharmaceutical Inc. has a 52 week low of $79.50 and a 52 week high of $100.51.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its earnings results on Thursday, October 26th. The biotechnology company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.06. The company had revenue of $334.18 million during the quarter, compared to the consensus estimate of $347.38 million. BioMarin Pharmaceutical had a negative return on equity of 4.60% and a negative net margin of 12.45%. The company’s revenue was up 19.4% on a year-over-year basis. During the same period last year, the firm earned $0.02 earnings per share. equities research analysts anticipate that BioMarin Pharmaceutical Inc. will post -0.65 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://sportsperspectives.com/2017/11/20/biomarin-pharmaceutical-inc-bmrn-holdings-lifted-by-los-angeles-capital-management-equity-research-inc.html.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply